US Patent

US10570453 — Method of predicting a predisposition to QT prolongation

Method of Use · Assigned to Vanda Pharmaceuticals Inc · Expires 2028-03-28 · 2y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for predicting a predisposition to QT prolongation and determining whether a compound, such as Milsaperidone, can induce it.

USPTO Abstract

The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4436 — milsaperidone
U-4437 — milsaperidone
U-4437 — milsaperidone
U-4437 — milsaperidone
U-4437 — milsaperidone
U-4437 — milsaperidone
U-4437 — milsaperidone

Patent Metadata

Patent number
US10570453
Jurisdiction
US
Classification
Method of Use
Expires
2028-03-28
Drug substance claim
No
Drug product claim
No
Assignee
Vanda Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.